Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥392.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)156.83K
Market Cap
¥6.87B
Enterprise Value¥12.28K
Total Cash (Recent Filing)¥3.96B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.81
Shares Outstanding16,868,100
10 Day Avg. Volume264,500
30 Day Avg. Volume156,826
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)3.59
Price to Sales (P/S)29.38
P/FCF Ratio-26.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.9
Revenue Forecast (FY)¥1.05B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthAn approximately 81% increase in annual revenue indicates improving commercial traction and expanding demand for the company’s offerings. If sustained, this growth can provide operating leverage, support reinvestment, and create a larger revenue base from which future profitability may develop.
Exceptionally High Gross MarginsGross margins of roughly 96–98% indicate that the current product and service mix retains substantial value after direct costs. This creates meaningful long-term earnings potential if revenue continues scaling and management can bring operating expenses into line with the expanding business.
Debt-free Balance SheetZero debt and a sizable equity base reduce solvency pressure and preserve financial flexibility while the company remains loss-making. This conservative funding structure gives management more time to pursue growth and limits the burden of interest expense or debt refinancing.
Bears Say
Large And Widening LossesLarge operating and net losses show that the current revenue base is not yet sufficient to cover the company’s cost structure. Continued losses can delay self-funded growth, weaken returns on capital, and make sustainable profitability dependent on substantial operating improvement.
Persistent Cash BurnPersistent negative operating and free cash flow indicate that the company is consuming cash as it operates, rather than funding investment internally. Continued burn can reduce financial resources over time and increase the importance of reaching profitability or securing additional equity capital.
Eroding Equity Base And Negative ReturnsFalling equity alongside negative returns on equity suggests that ongoing losses are consuming part of the capital base despite the absence of debt. If this pattern persists, financial resilience may gradually weaken and the company may have less capacity to absorb extended underperformance.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥392.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥6.87B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 54 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on Aug 07, 2026. The company reported -¥2.97 earnings per share for the quarter.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥2.97 in its last earnings report. Following the earnings report the stock price went up 0.999%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.